The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins.

The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The present invention relates to the field of antibodies and their application in food and feedstuff quality control. In particular, the invention relates to a method for the manufacture of an antibody that specifically binds to soy Gly m 8 protein wherein said method comprises immunising an animal with the purified soy Glym8 protein, wherein said soy Glym8 protein has been obtained by expressing soy Glym8 protein in plants, and preferably, tobacco plants and purifying the soy Glym8 protein from said plants and, preferably, tobacco plants and obtaining an antibody from the animal which specifically bind to soy Gly m8 protein, wherein the animal will be sacrificed. Moreover, the invention contemplates an antibody obtained by said method as well as the use of said antibody for detecting soy material in a food preparation or feedstuff preparation. Further, a method for detecting soy material in a food preparation or feedstuff preparation and a kit for carrying out said method are provided.

The present invention relates to the field of antibodies and their application in food and feedstuff quality control. In particular, the invention relates to a method for the manufacture of an antibody that specifically binds to soy Gly m 8 protein wherein said method comprises immunising an animal with the purified soy Glym8 protein, wherein said soy Glym8 protein has been obtained by expressing soy Glym8 protein in plants, and preferably, tobacco plants and purifying the soy Glym8 protein from said plants and, preferably, tobacco plants and obtaining an antibody from the animal which specifically bind to soy Gly m8 protein, wherein the animal will be sacrificed. Moreover, the invention contemplates an antibody obtained by said method as well as the use of said antibody for detecting soy material in a food preparation or feedstuff preparation. Further, a method for detecting soy material in a food preparation or feedstuff preparation and a kit for carrying out said method are provided.

The present disclosure provides a test strip for peanut immunofluorescence assay (IFA), use thereof and a detection method, and relates to the technical field of IFA. The test strip of the present disclosure includes a sample pad, a conjugate pad, a nitrocellulose membrane, and a wicking pad arranged successively on a PVC backing card in a left-to-right and end-to-end manner; fluorescent latex microsphere-labeled mixed antibodies are coated on the conjugate pad; anti-Ara h 1 antibody (T1 line), anti-Ara h 2 antibody (T2 line), anti-Ara h 3 antibody (T3 line), anti-total peanut protein (TPP) antibodies (T4 line), and rabbit anti-mouse IgG antibody (C line) are coated on the nitrocellulose membrane, where the T1, T2, T3, and T4 lines are test lines, and the C line is a control line.

The present disclosure provides a test strip for peanut immunofluorescence assay (IFA), use thereof and a detection method, and relates to the technical field of IFA. The test strip of the present disclosure includes a sample pad, a conjugate pad, a nitrocellulose membrane, and a wicking pad arranged successively on a PVC backing card in a left-to-right and end-to-end manner; fluorescent latex microsphere-labeled mixed antibodies are coated on the conjugate pad; anti-Ara h 1 antibody (T1 line), anti-Ara h 2 antibody (T2 line), anti-Ara h 3 antibody (T3 line), anti-total peanut protein (TPP) antibodies (T4 line), and rabbit anti-mouse IgG antibody (C line) are coated on the nitrocellulose membrane, where the T1, T2, T3, and T4 lines are test lines, and the C line is a control line.

The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.